<div id="readability-page-1"><p>Squarepoint Ops LLC purchased a new stake in  AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 2nd quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The fund purchased 109,388 shares of the biotechnology company's stock, valued at approximately $2,428,000. Squarepoint Ops LLC owned approximately 0.39% of AnaptysBio as of its most recent filing with the Securities &amp; Exchange Commission.</p><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p>Other institutional investors have also added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in  AnaptysBio by 2.7% during the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company's stock valued at $574,000 after buying an additional 826 shares in the last quarter.  US Bancorp DE lifted its holdings in shares of  AnaptysBio by 126.5% in the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after buying an additional 979 shares in the last quarter.  Corton Capital Inc. boosted its position in shares of  AnaptysBio by 12.2% in the second quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company's stock valued at $266,000 after acquiring an additional 1,305 shares during the period.  Tower Research Capital LLC TRC grew its stake in  AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 1,377 shares in the last quarter.  Finally, Swiss National Bank increased its holdings in  AnaptysBio by 9.1% during the 1st quarter. Swiss National Bank now owns 32,400 shares of the biotechnology company's stock worth $602,000 after acquiring an additional 2,700 shares during the period. </p><h2>Analyst Ratings Changes</h2><p>Several research analysts have commented on ANAB shares. HC Wainwright cut their price target on shares of AnaptysBio from $52.00 to $51.00 and set a &#34;buy&#34; rating for the company in a report on Monday, November 24th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of AnaptysBio in a research note on Wednesday, October 8th. Guggenheim boosted their target price on AnaptysBio from $90.00 to $100.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, November 5th. Barclays lowered their price target on AnaptysBio from $70.00 to $55.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday. Finally, Truist Financial lifted their price target on AnaptysBio from $20.00 to $36.00 and gave the company a &#34;hold&#34; rating in a research report on Monday, November 10th. One equities research analyst  has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned  a Hold rating and one  has given a Sell rating to the stock. According to data from MarketBeat, the company  has an average rating of &#34;Moderate Buy&#34; and an average target price of $55.40.</p><p><b>View Our Latest Stock Analysis on AnaptysBio</b></p><h2>AnaptysBio Stock Up 1.3%</h2><p>Shares of ANAB stock opened at $45.60 on Thursday. The business has a 50-day moving average price of $38.13 and a two-hundred day moving average price of $28.60. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $47.86. The firm has a market cap of $1.26 billion, a P/E ratio of -16.17 and a beta of 0.29. </p><p>AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. As a group, research analysts expect that  AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year. </p><p>AnaptysBio announced that its Board of Directors has authorized a share buyback program on Friday, November 21st that allows the company to repurchase $100.00 million in    shares. This repurchase authorization allows the biotechnology company to purchase up to 9.6% of its stock  through open market purchases. Stock  repurchase programs are often an indication that the company's board believes its stock is undervalued. </p><h2>AnaptysBio Company Profile</h2> (Free Report)<p>AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than AnaptysBio</li><li>How to Use the MarketBeat Stock Screener </li><li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li><li>What Makes a Stock a Good Dividend Stock?</li><li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li><li>High Dividend REITs: Are They an Ideal Way to Diversify?</li><li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li></ul><p><strong>Want to see what other hedge funds are holding ANAB?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5BQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5BQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AnaptysBio Right Now?</h2><p>Before you consider AnaptysBio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.</p><p>While AnaptysBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ANAB

<p>Squarepoint Ops LLC has invested $2.43 million in AnaptysBio, Inc. by purchasing 109,388 shares, representing 0.39% ownership. Other institutional investors have also adjusted their stakes. Analysts have mixed ratings on ANAB, with an average target price of $55.40. AnaptysBio's stock is up 1.3%, with a market cap of $1.26 billion. The company reported strong quarterly earnings and announced a $100 million share buyback program.</p>

Squarepoint Ops LLC Invests $2.43 Million in AnaptysBio, Inc. $ANAB